Curr Probl Cardiol. 2021 Aug 4:100956. doi: 10.1016/j.cpcardiol.2021.100956. Online ahead of print.
A high-intensity statin is recommended for the secondary prevention of cardiovascular diseases (CVD). However, real-world evidence of the effectiveness of rosuvastatin following acute coronary syndrome (ACS) is scarce. This retrospective cohort study included patients diagnosed with ACS to compare between the two high-intensity statin therapies (rosuvastatin versus atorvastatin) in terms of a primary composite outcome of CVD-associated death, non-fatal ACS, and non-fatal stroke at 1 month and 12 months post-discharge. The primary effectiveness outcome did not differ between the two groups at 1 month (1.3% vs. 1%; aHR = 1.64, 95% CI 0.55-4.94, p= 0.379) and at 12 months (4.8% vs. 3.5%; aHR = 1.48, 95% CI 0.82-2.67, p= 0.199). Similarly, the two groups had comparable safety outcomes. In conclusion, the use of high-intensity rosuvastatin compared to high-intensity atorvastatin therapy in patients with ACS had resulted in comparable cardiovascular effectiveness and safety outcomes.